X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-09-01 | MNKD | Castagna Michael | CEO | S - Sale | $4.61 | -10,000 | 2,369,147 | 0% | -$46,100 | ||||||
2023-08-28 | MNKD | Thomson David | EVP Genl Counsel, Secretary | S - Sale | $4.78 | -8,100 | 798,835 | -1% | -$38,738 | ||||||
2023-08-01 | MNKD | Castagna Michael | CEO | S - Sale | $4.57 | -10,000 | 2,496,735 | 0% | -$45,686 | ||||||
| AM | 2023-07-03 | MNKD | Castagna Michael | CEO | S - Sale | $4.04 | -10,000 | 2,506,735 | 0% | -$40,373 | |||||
2023-07-03 | MNKD | Castagna Michael | CEO | S - Sale | $4.07 | -10,000 | 2,506,735 | 0% | -$40,701 | ||||||
2023-06-01 | MNKD | Castagna Michael | CEO | S - Sale | $4.53 | -10,000 | 2,516,735 | 0% | -$45,302 | ||||||
| DM | 2023-05-25 | MNKD | Castagna Michael | CEO | S - Sale+OE | $4.55 | -150,000 | 2,526,735 | -6% | -$681,803 | |||||
2023-05-24 | MNKD | Thomson David | EVP Genl Counsel, Secretary | S - Sale | $4.68 | -95,576 | 735,263 | -12% | -$447,754 | ||||||
2023-05-24 | MNKD | Castagna Michael | CEO | S - Sale | $4.69 | -150,000 | 2,331,735 | -6% | -$702,780 | ||||||
2023-05-24 | MNKD | Binder Steven B. | CFO | S - Sale | $4.68 | -47,810 | 838,324 | -5% | -$223,512 | ||||||
2023-05-05 | MNKD | Castagna Michael | CEO | S - Sale | $4.00 | -10,000 | 2,020,128 | 0% | -$40,000 | ||||||
2023-04-03 | MNKD | Castagna Michael | CEO | S - Sale | $4.13 | -10,000 | 2,030,128 | 0% | -$41,287 | ||||||
2023-03-01 | MNKD | Castagna Michael | CEO | S - Sale | $5.27 | -10,000 | 2,040,128 | 0% | -$52,748 | ||||||
2022-08-29 | MNKD | Thomson David | EVP Genl Counsel, Secretary | S - Sale | $3.67 | -7,000 | 726,035 | -1% | -$25,690 | ||||||
2022-08-22 | MNKD | Galindo Alejandro | EVP Endocrine Business Unit | S - Sale | $3.85 | -4,615 | 777,075 | -1% | -$17,771 | ||||||
2022-07-31 | MNKD | Binder Steven B. | CFO | P - Purchase | $2.93 | +791 | 728,997 | 0% | +$2,318 | ||||||
2022-07-31 | MNKD | Castagna Michael | CEO | P - Purchase | $2.93 | +3,147 | 2,084,486 | 0% | +$9,221 | ||||||
2022-07-31 | MNKD | Tross Stuart A | Chief People, Workpl Officer | P - Purchase | $2.93 | +4,581 | 830,650 | +1% | +$13,422 | ||||||
2022-07-31 | MNKD | Galindo Alejandro | EVP Endocrine Business Unit | P - Purchase | $2.93 | +5,000 | 781,690 | +1% | +$14,650 | ||||||
2022-02-28 | MNKD | Galindo Alejandro | Chief Commercial Officer | P - Purchase | $2.71 | +36,900 | 576,690 | +7% | +$99,999 | ||||||
2022-02-28 | MNKD | Hooper Anthony C | Dir | P - Purchase | $2.71 | +40,000 | 338,394 | +13% | +$108,400 | ||||||
2022-02-28 | MNKD | Mundkur Christine | Dir | P - Purchase | $2.71 | +27,675 | 254,493 | +12% | +$74,999 | ||||||
| A | 2022-01-31 | MNKD | Galindo Alejandro | Chief Commercial Officer | P - Purchase | $3.17 | +1,804 | 539,790 | 0% | +$5,719 | |||||
| A | 2022-01-31 | MNKD | Castagna Michael | CEO | P - Purchase | $3.17 | +1,804 | 1,505,098 | 0% | +$5,719 | |||||
| A | 2022-01-31 | MNKD | Tross Stuart A | Chief People, Workpl Officer | P - Purchase | $3.17 | +2,254 | 622,785 | 0% | +$7,145 | |||||
2022-01-31 | MNKD | Binder Steven B. | CFO | P - Purchase | $3.17 | +711 | 534,178 | 0% | +$2,254 | ||||||
2022-01-31 | MNKD | Galindo Alejandro | Chief Commercial Officer | P - Purchase | $3.17 | +2,334 | 540,320 | 0% | +$7,399 | ||||||
2022-01-31 | MNKD | Tross Stuart A | Chief People, Workpl Officer | P - Purchase | $3.17 | +4,254 | 624,785 | +1% | +$13,485 | ||||||
2022-01-31 | MNKD | Castagna Michael | CEO | P - Purchase | $3.17 | +2,334 | 1,505,628 | 0% | +$7,399 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |